EFNA1 and cancer: In patients with early-stage GC, we also observed the diagnostic ability of serum EFNA1 combined with MMP13 to distinguish cancer patients from normal controls (AUC 0.865, sensitivity 48.5%, specificity 90.2%) (Fig. 3A and Table 3, Supplementary excel).